Tubeimoside I ameliorates cerebral ischemia/reperfusion injury through activating SIRT3

Shaoyue Huang, Zhen Hong, Kuo Li
{"title":"Tubeimoside I ameliorates cerebral ischemia/reperfusion injury through activating SIRT3","authors":"Shaoyue Huang, Zhen Hong, Kuo Li","doi":"10.15586/qas.v15i2.1263","DOIUrl":null,"url":null,"abstract":"Cerebral ischemia-reperfusion (CIR) seriously affects human health and life as it is accompanied by inflammation and apoptosis in brain tissues. Tubeimoside I (TBMS-1) can inhibit neuroinflammation and has neuroprotective effects; however, its effects on ischemia-reperfusion (IR) injury of the brain requires clarity. A mouse cerebral artery occlusion/reperfusion model was used to simulate CIR injury. The neurological function and the area of cerebral infarction were assessed by 2,3,5-triphenyltetrazolium chloride staining. Tumor necrosis factor-α, Interleukin (IL)-1β, IL-6, and IL-10 levels were measured by enzyme-linked-immunosorbent serologic assay kits. Protein blot analysis was performed to assess the expression of apoptosis-related factors. In addition, PC12 (pheo-chromocytoma) cells were treated with oxygen–glucose deprivation/reoxygenation (OGD/R) to establish an in vitro model of CIR injury. The cell viability was measured by cell counting kit-8 assay, and apoptosis levels were detected by flow cytometry. In vivo results indicated that Tubeimoside I reduced cerebral infarct size, decreased inflammatory factor content, inhibited the expression of apoptosis-related factors, including Bax and cleaved-caspase-3 (Asp175), and promoted the expression of survival factor, such as B-cell lymphoma protein 2. In vitro, Tubeimoside I was able to increase cell viability and inhibit apoptosis. Mechanistically, Tubeimoside I was able to enhance both in vivo and in vitro expressions of NAD-dependent deacetylase sirtuin-3 (SIRT3). SIRT3 inhibitor abolished the protective effect of Tubeimoside I on OGD/R-treated cells. Tubeimoside I lessened CIR injury by activating SIRT3. Hence, it could be a potential drug candidate for treating IR injury of the brain.","PeriodicalId":20738,"journal":{"name":"Quality Assurance and Safety of Crops & Foods","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quality Assurance and Safety of Crops & Foods","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15586/qas.v15i2.1263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cerebral ischemia-reperfusion (CIR) seriously affects human health and life as it is accompanied by inflammation and apoptosis in brain tissues. Tubeimoside I (TBMS-1) can inhibit neuroinflammation and has neuroprotective effects; however, its effects on ischemia-reperfusion (IR) injury of the brain requires clarity. A mouse cerebral artery occlusion/reperfusion model was used to simulate CIR injury. The neurological function and the area of cerebral infarction were assessed by 2,3,5-triphenyltetrazolium chloride staining. Tumor necrosis factor-α, Interleukin (IL)-1β, IL-6, and IL-10 levels were measured by enzyme-linked-immunosorbent serologic assay kits. Protein blot analysis was performed to assess the expression of apoptosis-related factors. In addition, PC12 (pheo-chromocytoma) cells were treated with oxygen–glucose deprivation/reoxygenation (OGD/R) to establish an in vitro model of CIR injury. The cell viability was measured by cell counting kit-8 assay, and apoptosis levels were detected by flow cytometry. In vivo results indicated that Tubeimoside I reduced cerebral infarct size, decreased inflammatory factor content, inhibited the expression of apoptosis-related factors, including Bax and cleaved-caspase-3 (Asp175), and promoted the expression of survival factor, such as B-cell lymphoma protein 2. In vitro, Tubeimoside I was able to increase cell viability and inhibit apoptosis. Mechanistically, Tubeimoside I was able to enhance both in vivo and in vitro expressions of NAD-dependent deacetylase sirtuin-3 (SIRT3). SIRT3 inhibitor abolished the protective effect of Tubeimoside I on OGD/R-treated cells. Tubeimoside I lessened CIR injury by activating SIRT3. Hence, it could be a potential drug candidate for treating IR injury of the brain.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Tubeimoside I通过激活SIRT3改善脑缺血/再灌注损伤
脑缺血再灌注(Cerebral ischemic -reperfusion, CIR)是一种伴有脑组织炎症和细胞凋亡的疾病,严重影响人类健康和生命。Tubeimoside I (TBMS-1)能抑制神经炎症,具有神经保护作用;然而,其对脑缺血再灌注(IR)损伤的影响尚不清楚。采用小鼠脑动脉闭塞/再灌注模型模拟CIR损伤。采用2,3,5-三苯四唑氯染色法观察大鼠神经功能及脑梗死面积。采用酶联免疫吸附血清学检测试剂盒检测肿瘤坏死因子-α、白细胞介素(IL)-1β、IL-6和IL-10水平。蛋白印迹法检测细胞凋亡相关因子的表达。此外,采用氧-葡萄糖剥夺/再氧化(OGD/R)处理PC12(嗜铬细胞瘤)细胞,建立体外CIR损伤模型。采用细胞计数试剂盒-8检测细胞活力,流式细胞术检测细胞凋亡水平。体内实验结果显示,Tubeimoside I可减小脑梗死面积,降低炎症因子含量,抑制凋亡相关因子Bax、裂解caspase-3 (Asp175)的表达,促进b细胞淋巴瘤蛋白2等存活因子的表达。在体外,Tubeimoside I能够提高细胞活力,抑制细胞凋亡。从机制上讲,Tubeimoside I能够增强nad依赖性去乙酰化酶sirtuin-3 (SIRT3)在体内和体外的表达。SIRT3抑制剂可消除Tubeimoside I对OGD/ r处理细胞的保护作用。Tubeimoside I通过激活SIRT3减轻CIR损伤。因此,它可能是治疗脑IR损伤的潜在候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A beetroot-based beverage produced by adding Lacticaseibacillus paracasei: an optimization study Safety evaluation of genetically modified crops Effect of pullulan active packaging, incorporated with silver nanoparticles, on cholesterol oxidation product concentrations in boiler meat during storage Sustainable rural economy and food security: An integrated approach to the circular agricultural model Mechanistic insight into ochratoxin A adsorption onto the cell wall of Lacticaseibacillus rhamnosus Bm01 and its impact on grape juice quality
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1